Grand Pharmaceutical Group Ltd
HKEX:512
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
3.28
5.62
|
| Price Target |
|
We'll email you a reminder when the closing price reaches HKD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Grand Pharmaceutical Group Ltd
Other Liabilities
Grand Pharmaceutical Group Ltd
Other Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
G
|
Grand Pharmaceutical Group Ltd
HKEX:512
|
Other Liabilities
HK$243.6m
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
-5%
|
|
|
U
|
United Laboratories International Holdings Ltd
HKEX:3933
|
Other Liabilities
¥27.2m
|
CAGR 3-Years
-25%
|
CAGR 5-Years
-17%
|
CAGR 10-Years
-11%
|
|
|
Sino Biopharmaceutical Ltd
HKEX:1177
|
Other Liabilities
¥671m
|
CAGR 3-Years
5%
|
CAGR 5-Years
10%
|
CAGR 10-Years
24%
|
|
|
C
|
China Traditional Chinese Medicine Holdings Co Ltd
HKEX:570
|
Other Liabilities
¥407.1m
|
CAGR 3-Years
1%
|
CAGR 5-Years
18%
|
CAGR 10-Years
31%
|
|
|
C
|
China Resources Pharmaceutical Group Ltd
HKEX:3320
|
Other Liabilities
HK$1.9B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
|
|
H
|
HUTCHMED (China) Ltd
HKEX:13
|
Other Liabilities
$79.9m
|
CAGR 3-Years
144%
|
CAGR 5-Years
59%
|
CAGR 10-Years
N/A
|
|
Grand Pharmaceutical Group Ltd
Glance View
Grand Pharmaceutical Group Ltd. stands as a significant player in the pharmaceutical industry, strategically positioned in the bustling hub of the Asia-Pacific region. Founded with a vision to harness scientific innovation for healing, the company has diligently expanded its reach and capabilities over the years. Grand Pharma is meticulously structured around three core segments: Medicine and Healthcare, Biopharmaceutical Manufacturing, and Medical Devices. In the Medicine and Healthcare segment, it advances an extensive portfolio of both proprietary and generic drugs. This segment alone accounts for a substantial portion of its revenue, capitalizing on its adeptness in research and development to maintain a robust pipeline of products. By continuously innovating and seeking to meet unmet medical needs, Grand Pharma sustains its competitive edge in the market. Their Biopharmaceutical Manufacturing segment shines brightly as a beacon of future growth, showcasing their commitment to biotechnology. Here, Grand Pharmaceutical leverages cutting-edge biotechnologies to develop therapies targeting a range of complex diseases. This segment is noted for its high-margin potential, driven by the increasing global demand for biologics. Furthermore, their Medical Devices segment complements the pharmaceutical operations by delivering state-of-the-art products in areas such as cardiovascular health and surgical equipment. By maintaining a balanced and diversified portfolio across these business areas, Grand Pharmaceutical effectively mitigates risks and capitalizes on emerging trends in global healthcare markets. Through astute strategic planning and an unwavering commitment to quality and innovation, the company fortifies its position as a leader in the field, continually reinvesting its profits to further enhance its offerings and broaden its impact.
See Also
What is Grand Pharmaceutical Group Ltd's Other Liabilities?
Other Liabilities
243.6m
HKD
Based on the financial report for Jun 30, 2024, Grand Pharmaceutical Group Ltd's Other Liabilities amounts to 243.6m HKD.
What is Grand Pharmaceutical Group Ltd's Other Liabilities growth rate?
Other Liabilities CAGR 10Y
-5%
Over the last year, the Other Liabilities growth was 7%. The average annual Other Liabilities growth rates for Grand Pharmaceutical Group Ltd have been -5% over the past three years , -16% over the past five years , and -5% over the past ten years .
You don't have any saved screeners yet
